Working… Menu
Trial record 1 of 1 for:    NCT00110396
Previous Study | Return to List | Next Study

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (RNF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00110396
Recruitment Status : Completed
First Posted : May 9, 2005
Results First Posted : July 9, 2010
Last Update Posted : July 15, 2015
Information provided by:
EMD Serono

Tracking Information
First Submitted Date  ICMJE May 6, 2005
First Posted Date  ICMJE May 9, 2005
Results First Submitted Date  ICMJE April 30, 2010
Results First Posted Date  ICMJE July 9, 2010
Last Update Posted Date July 15, 2015
Study Start Date  ICMJE January 2005
Actual Primary Completion Date April 2007   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 14, 2010)
Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. [ Time Frame: 96 weeks ]
The NAb positive value was defined as NAb value greater or equal to 20 NU/mL. NAbs were detected using a viral cytopathic assay.
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 14, 2010)
  • Number of Participants Who Were Neutralising Antibody (NAb) Positive at Anytime During the Study [ Time Frame: 96 weeks ]
    The NAb positive value was defined as NAb value greater or equal to 20 NU/mL. NAbs were detected using a viral cytopathic assay.
  • Number of Participants With Binding Antibodies (BAb) at Week 96 [ Time Frame: 96 weeks ]
    Presence of BAbs. BAbs were measured by ELISA (Enzyme-linked immunosorbent assay).
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
Official Title  ICMJE A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis
Brief Summary The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
Detailed Description As has been seen with other recombinant protein molecules, the use of injectable recombinant proteins may result in the development of neutralising antibodies (NAbs). Antibodies are considered neutralising by their ability to inhibit the biological effect of interferon in a bioassay system. EMD Serono has actively pursued improvements in the formulation of interferon (IFN) beta-1a to reduce aggregate levels and to develop a formulation that is HSA-free. Reducing aggregates should reduce antigenicity of the product while removal of HSA may have an unpredictable effect on antigenicity. EMD Serono will conduct a study to assess the immunogenicity and safety of the new HSA-free formulation, manufactured using IFN-ß-1a drug substance produced by a new clone from the FBS-free process.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Multiple Sclerosis
Intervention  ICMJE Biological: Interferon-beta-1a FBS-free/HSA-free
Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
Study Arms  ICMJE Experimental: Rebif New Formulation Cohort
Intervention: Biological: Interferon-beta-1a FBS-free/HSA-free
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 14, 2010)
Original Enrollment  ICMJE
 (submitted: June 23, 2005)
Actual Study Completion Date  ICMJE April 2007
Actual Primary Completion Date April 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participant has a relapsing form of Multiple Sclerosis (MS); diagnosis of MS is in accordance with the McDonald criteria
  • Participant is eligible for interferon therapy
  • Participant is between 18 and 60 years old
  • Participant has an Expanded Disability Status Scale (EDSS) < 6.0.
  • Participant is willing to follow study procedures
  • Participant has given written informed consent
  • Female participants must be neither pregnant nor breast-feeding, and must lack childbearing potential, as defined by either:
  • Being post-menopausal or surgically sterile, or
  • Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study.
  • Confirmation that the participant is not pregnant must be established by a negative serum or urinary hCG test within 7 days prior to start of study treatment. A pregnancy test is not required if the participant is post-menopausal or surgically sterile.

Exclusion Criteria:

  • Participant has a Clinically Isolated Syndrome (CIS), Primary Progressive MS, or Secondary Progressive MS without superimposed relapses.
  • Participant had any prior interferon beta therapy (either beta-1b or beta-1a)
  • Participant has an ongoing MS relapse.
  • Participant received any other approved disease modifying therapy for MS (e.g. glatiramer acetate) or any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 1(SD1).
  • Participant had prior use of cladribine or has previously received total lymphoid irradiation.
  • Participant received oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 30 days of SD1.
  • Participant received intravenous immunoglobulins or underwent plasmapheresis within the 6 months prior to SD1.
  • Participant received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, Campath) within the 12 months prior to SD1.
  • Participant requires chronic or monthly pulse corticosteroids during the study.
  • Participant received any investigational drug or experimental procedure within 12 weeks of SD1.
  • Participant has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase > 2.5 times the upper limit of the normal values.
  • Participant has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal.
  • Participant suffers from current autoimmune disease.
  • Participant suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol.
  • Participant has a known allergy to IFN or the excipients.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00110396
Other Study ID Numbers  ICMJE 25632
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Susan Fischer, EMD Serono Inc
Study Sponsor  ICMJE EMD Serono
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director: Bettina Stubinski, MD Merck Serono SA - Geneva
PRS Account EMD Serono
Verification Date June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP